Literature DB >> 26876244

Brain fluorodeoxyglucose (FDG) PET in dementia.

Takashi Kato1, Yoshitaka Inui2, Akinori Nakamura3, Kengo Ito4.   

Abstract

The purpose of this article is to present a selective and concise summary of fluorodeoxyglucose (FDG) positron emission tomography (PET) in dementia imaging. FDG PET is used to visualize a downstream topographical marker that indicates the distribution of neural injury or synaptic dysfunction, and can identify distinct phenotypes of dementia due to Alzheimer's disease (AD), Lewy bodies, and frontotemporal lobar degeneration. AD dementia shows hypometabolism in the parietotemporal association area, posterior cingulate, and precuneus. Hypometabolism in the inferior parietal lobe and posterior cingulate/precuneus is a predictor of cognitive decline from mild cognitive impairment (MCI) to AD dementia. FDG PET may also predict conversion of cognitively normal individuals to those with MCI. Age-related hypometabolism is observed mainly in the anterior cingulate and anterior temporal lobe, along with regional atrophy. Voxel-based statistical analyses, such as statistical parametric mapping or three-dimensional stereotactic surface projection, improve the diagnostic performance of imaging of dementias. The potential of FDG PET in future clinical and methodological studies should be exploited further.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Dementia; FDG PET; Fluorodeoxyglucose; Mild cognitive impairment; Preclinical AD

Mesh:

Substances:

Year:  2016        PMID: 26876244     DOI: 10.1016/j.arr.2016.02.003

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  55 in total

Review 1.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

2.  Functional survival forests for multivariate longitudinal outcomes: Dynamic prediction of Alzheimer's disease progression.

Authors:  Jeffrey Lin; Kan Li; Sheng Luo
Journal:  Stat Methods Med Res       Date:  2020-07-29       Impact factor: 3.021

3.  Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline.

Authors:  Nare Torosyan; Kelsey Mason; Magnus Dahlbom; Daniel H S Silverman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-22       Impact factor: 9.236

4.  Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astrogliosis in Streptozotocin-Induced Alzheimer's Rat Model.

Authors:  Yanxing Chen; Zhangyu Guo; Yan-Fang Mao; Tingting Zheng; Baorong Zhang
Journal:  Neurotox Res       Date:  2017-09-19       Impact factor: 3.911

5.  SIRT3 Haploinsufficiency Aggravates Loss of GABAergic Interneurons and Neuronal Network Hyperexcitability in an Alzheimer's Disease Model.

Authors:  Aiwu Cheng; Jing Wang; Nathaniel Ghena; Qijin Zhao; Isabella Perone; Todd M King; Richard L Veech; Myriam Gorospe; Ruiqian Wan; Mark P Mattson
Journal:  J Neurosci       Date:  2019-12-09       Impact factor: 6.167

6.  Brain connectivity markers in advanced Parkinson's disease for predicting mild cognitive impairment.

Authors:  Hai Lin; Zesi Liu; Wei Yan; Doudou Zhang; Jiali Liu; Bin Xu; Weiping Li; Qiusheng Zhang; Xiaodong Cai
Journal:  Eur Radiol       Date:  2021-06-09       Impact factor: 5.315

7.  Binding of the synaptic vesicle radiotracer [11C]UCB-J is unchanged during functional brain activation using a visual stimulation task.

Authors:  Kelly Smart; Heather Liu; David Matuskey; Ming-Kai Chen; Kristen Torres; Nabeel Nabulsi; David Labaree; Jim Ropchan; Ansel T Hillmer; Yiyun Huang; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2020-08-05       Impact factor: 6.200

Review 8.  Frontotemporal dementia: latest evidence and clinical implications.

Authors:  Juan Joseph Young; Mallika Lavakumar; Deena Tampi; Silpa Balachandran; Rajesh R Tampi
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-10

Review 9.  Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential.

Authors:  Yashi Mi; Guoyuan Qi; Roberta Diaz Brinton; Fei Yin
Journal:  Antioxid Redox Signal       Date:  2020-04-21       Impact factor: 8.401

Review 10.  Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases.

Authors:  Christopher G Schwarz
Journal:  Neurotherapeutics       Date:  2021-03-15       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.